Autolus COO discloses initial share and option holdings
Autolus Therapeutics plc Chief Operating Officer Christopher Andrew Vann filed an initial ownership report showing a mix of ordinary shares, American Depositary Shares (ADSs), options and restricted share units (RSUs).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Autolus Therapeutics plc Chief Operating Officer Christopher Andrew Vann filed an initial ownership report showing a mix of ordinary shares, American Depositary Shares (ADSs), options and restricted share units (RSUs).
He directly holds 152,211 Ordinary Shares and 40,000 ADSs, with each ADS currently representing one ordinary share and being convertible on a one-for-one basis. He also has several option awards over ADSs, including 500,000 ADSs at an exercise price of $1.89 expiring in 2035 and 375,000 ADSs at $1.46 expiring in 2036, alongside other grants at higher exercise prices with earlier expirations. In addition, he holds 83,300 RSUs, each representing a right to receive one ADS. Certain options are already fully vested and exercisable, while others and the RSUs vest over multi-year schedules in equal installments.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (10)
- F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one ordinary share.
- F2. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
- F3. Fully vested and exercisable.
- F4. This option vested 25% on July 22, 2023 and the remainder vests in 36 equal monthly installments thereafter.
- F5. This option vested 25% on March 6, 2024 and the remainder vests in 36 equal monthly installments thereafter.
- F6. This option vested 25% on October 12, 2024 and the remainder vests in 36 equal monthly installments thereafter.
- F7. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.
- F8. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.
- F9. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.
- F10. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing for Autolus Therapeutics (AUTL) show for Christopher Vann?
What option awards over Autolus Therapeutics ADSs does Christopher Vann report?
How do Christopher Vann’s options and RSUs in AUTL vest over time?
What are the key RSU holdings reported for Autolus Therapeutics COO Christopher Vann?
AI-generated analysis. How Rhea-AI works. Not financial advice.
